The TGF-β sequester GC1008 (also known as Fresolimumab), one of the best characterized monoclonal anti-TGF-β1-3 antibodies was used in patients with renal cell carcinoma (phase I, NCT00923169), melanoma (phases I and II, NCT00923169), glioma (phase II, NCT01472731), mesothelioma (phase II, NCT01112293), and breast cancer (phase II, NCT01401062). The gene discussed is TGFB1; the disease is central nervous system cancer.